Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jul;205(1):329-334.
doi: 10.1111/bjh.19561. Epub 2024 May 23.

Sputum interleukin-6 level as a marker of severity during acute chest syndrome in children with sickle cell disease

Lara Mayrand  1   2 , Juliette Elie  1   2 , Yael Pinhas  2   3 , Rachel Rignault-Bricard  1   3 , Melissa Taylor  2   3 , Joséphine Brice  2   3 , Mariane de Montalembert  2   3 , Claire Heilbronner  4 , Agathe Beranger  4   5 , Sofia Angyalosy  4 , Stephanie Chhun  6 , Thiago Trovati Maciel  1   3 , Olivier Hermine  1   3   7   8 , Slimane Allali  1   2   3
Affiliations
Observational Study

Sputum interleukin-6 level as a marker of severity during acute chest syndrome in children with sickle cell disease

Lara Mayrand et al. Br J Haematol. 2024 Jul.

Abstract

Acute chest syndrome (ACS) is a leading cause of morbimortality in sickle cell disease (SCD). In this prospective observational study, we investigated sputum interleukin-6 (IL-6) level as an ACS severity marker during 30 ACS episodes in 26 SCD children. Sputum IL-6 levels measured within the first 72 h of hospitalisation for ACS were significantly higher in patients with oxygen requirement ≥2 L/min, ventilation (invasive and/or non-invasive) length ≥5 days, bilateral and/or extensive opacities on chest X-ray or erythrocytapheresis requirement. Sputum IL-6 could serve as an ACS severity marker to help identify patients requiring targeted anti-inflammatory treatments such as tocilizumab.

Keywords: acute chest syndrome; interleukin‐6; paediatric; severity marker; sickle cell disease.

PubMed Disclaimer

References

REFERENCES

    1. Bartram JL, Thein SL, Gardner K, Egberongbe Y, D'Silva P, Height SE, et al. Outcome of children with sickle cell disease admitted to intensive care – a single institution experience. Br J Haematol. 2010;150:614–617.
    1. Cecchini J, Lionnet F, Djibre M, Parrot A, Stojanovic KS, Girot R, et al. Outcomes of adult patients with sickle cell disease admitted to the ICU: a case series. Crit Care Med. 2014;42:1629–1639.
    1. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342:1855–1865.
    1. Jain S, Bakshi N, Krishnamurti L. Acute chest syndrome in children with sickle cell disease. Pediatr Allergy Immunol Pulmonol. 2017;30:191–201.
    1. Allali S, de Montalembert M, Rignault‐Bricard R, Taylor M, Brice J, Brousse V, et al. IL‐6 levels are dramatically high in the sputum from children with sickle cell disease during acute chest syndrome. Blood Adv. 2020;4:6130–6134.

Publication types

LinkOut - more resources